Carisa S. De Anda, PharmD

Executive Director, Clinical Research
Merck & Co., Inc.

Disclosure(s): Merck & Co., Inc.: Employee of Merck & Co., Inc., MOV patent, Stocks/Bonds (Public Company)

Poster(s):

• (P-1928) Virologic and Clinical Outcomes Among Participants Hospitalized in a Phase 3 Trial Comparing Molnupiravir with Placebo for Treating Mild-to-Moderate COVID-19
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT